2383086-06-2
2383086-06-2
Chemical Structure
Sonrotoclax
Synonym(s): BGB 11417
- No. CAS: 2383086-06-2
- Formula:C49H59N7O7S
- Molecular Weight:890.10
IUPAC Name: 1-(tert-butyl) 2-methyl 4-bromo-3-chloro-1H-pyrrole-1,2-dicarboxylate
InChIKey: ZQTKOYMWCCSKON-XKXNWSITSA-N
SMILES: CC(C1=C(C=CC=C1)[C@H]2N(CCC2)C3CC4(CCN(C5=CC(OC6=CN=C(NC=C7)C7=C6)=C(C=C5)C(NS(=O)(C8=CC([N+]([O-])=O)=C(C=C8)NC[C@@H]9CC[C@@](O)(CC9)C)=O)=O)CC4)C3)C
Biological Activity: Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines[1].
| Referencia número | Nombre del producto | Pureza | Descripciòn | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sonrotoclax | 99.61% | Sonrotoclax is a potent, orally active Bcl2 inhibitor. Sonrotoclax has effective cell killing effect against a variety of lymphoma and leukemia cell lines. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lisaftoclax | 99.78% | Lisaftoclax is an orally active, selective BCL-2 inhibitor with a Ki of < 0.1 nM against human BCL-2. Lisaftoclax selectively binds to BCL-2, disrupts the BCL-2:BIM complex, and antagonizes the antiapoptotic function of BCL-2. Lisaftoclax induces BAX/BAK-dependent, caspase-mediated apoptosis, upregulates the pro-death proteins BIM and Noxa, and downregulates mitochondrial respiratory function and ATP production. Lisaftoclax can be used in the research of hematological malignancies including chronic lymphocytic leukemia, multiple myeloma, and diffuse large B-cell lymphoma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(Rac)-Lisaftoclax | 98.22% | (Rac)-Lisaftoclax ((Rac)-APG-2575) is a Bcl-2 inhibitor that can be uesd for hematologic malignancy research (CN112898295A). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bcl-2-IN-2 | Bcl-2-IN-2 is a potent and selective Bcl-2 inhibitor with an IC50 of 0.034 nM and also inhibits Bcl-xL with an IC50 of 43 nM, showing >1000-fold selectivity for Bcl-2 over Bcl-xL. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Venetoclax N-oxide | 99.66% | Venetoclax N-oxide is an impurity of Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
A-1211212 | 98.43% | A-1211212 (BCL2-IN-1), a chemical probe, is a potent Bcl-2 inhibitor. BCL2-IN-1 binds Bcl-2 with a Ki of <0.01 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Bcl-2-IN-5 | Bcl-2-IN-5 is a BCL-2 inhibitor with IC50s of 0.12 nM, 0.14 nM and 0.22 nM for Bcl-2 wild type, Bcl-2 D103Y and Bcl-2 G101V, respectively. Bcl-2-IN-5 inhibits the cell growth with IC50 values of 0.2 nM and 0.44 nM for Bcl 2-G101V knock-in RS4; 11 and RS4; 11 cells, respectively (WO2021208963A1; Example 155). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Venetoclax | 99.95% | Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a Ki of less than 0.01 nM. Venetoclax induces autophagy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Asaretoclax | Asaretoclax is a potent B-cell lymphoma 2 (Bcl-2) inhibitor. Asaretoclax has the potential for the research of cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mesutoclax | 98.69% | Mesutoclax (ICP-248) (Compound 5) is a selective BCL-2 inhibitor with an IC50 of 1.54 nM. Mesutoclax has weak activity against BCL-XL (IC50: ＞1000 nM). Mesutoclax can inhibit the activity of RS4;11 cells with an IC50 of 2.75 nM. Mesutoclax can be used in the study of cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
